Compare Coursera Inc (COUR) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Novartis AG — how do they compare? Coursera Inc trades at $5.28 (market cap $1.39B), while Novartis AG trades at $142.74 (market cap $268.57B). The key difference: Novartis AG is far larger — about 193.2× Coursera Inc's market cap, and Novartis AG pays a 3.31% dividend while Coursera Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Novartis AG for 82 Days on average.
| COUR | NVS | |
|---|---|---|
Market Cap | $1.39B | $268.57B |
Volume | 9,728,980 | 1,532,573 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $168.62 |
52-Week Low | $4.64 | $121.80 |
Typical Hold Time | 47 Days | 82 Days |
Enterprise Value | $648.49M | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.11, down 0.2% on the day, with a bearish technical signal and neutral oscillators. Revenue has grown from $524M in 2022 to $757.5M in 2025, but the company remains unprofitable with a net loss of $51M in 2025. Recent news highlights AI platform developments and significant institutional buying interest.
The stock offers potential upside to the $7.40 analyst consensus target but faces risks from persistent losses and competitive pressures. Positive cash flow and subscriber growth are key strengths, yet profitability challenges and integration costs from recent acquisitions present headwinds for near-term performance.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
